Background Isatuximab is a monoclonal antibody that binds a specific epitope on the human
CD38 receptor and has antitumour activity via multiple mechanisms of action. In a previous …

Background Selinexor combined with dexamethasone has shown activity in patients with
heavily pre-treated multiple myeloma. In a phase 1b/2 study, the combination of oral selinexor …

Achieving and maintaining a high-quality response is the treatment goal for patients with
newly diagnosed multiple myeloma (NDMM). The phase 3 PETHEMA/GEM2012 study, in 458 …

The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more
frequently investigated in transplant-eligible patients than in elderly patients. Because an …

Detecting persistent minimal residual disease (MRD) allows the identification of patients
with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months …

Recent studies have shown a suboptimal humoral response to severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines in patients …

There is limited information on the characteristics, prognostic factors, and outcomes of patients
with multiple myeloma (MM) hospitalized with COVID-19. This retrospective case series …

Background Melphalan flufenamide (melflufen), an alkylating peptide-drug conjugate, plus
dexamethasone showed clinical activity and manageable safety in the phase 2 HORIZON …

Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is
associated with inferior survival in multiple myeloma (MM). Thus, characterization of the minor …

Tumor recognition by T cells is essential for antitumor immunity. A comprehensive
characterization of T cell diversity may be key to understanding the success of immunomodulatory …